Clinical characteristics of the patients with confirmed or suspected COVID-19
| Confirmed COVID-19 | Clinical picture highly suggestive of COVID-19 | Contact with a known COVID-19 patient | |
| Number of patients | 4 | 4 | 5 |
| Age (years) (mean±SD) | 58±5 | 56±8 | 54±12 |
| Female, n (%) | 4 (100) | 3 (75) | 4 (80) |
| Comorbidities, n (%) | |||
| Hypertension | 1 (25) | 2 (50) | 1 (20) |
| Diabetes | 0 | 0 | 0 |
| Cardiovascular disease | 0 | 0 | 1 (20) |
| Other | 4 (100) | 4 (100) | 3 (60) |
| Smoking, n (%) | |||
| Active | 1 (25) | 0 | 0 |
| Previous | 2 (50) | 3 (75) | 1 (20) |
| Rheumatological diagnosis | |||
| RA, n (%) | 3 (75) | 3 (75) | 5 (100) |
| SpA/PA,* n (%) | 1 (25) | 1* (25) | 0 |
| Rheumatological treatment, n (%) | |||
| bDMARD | |||
| Adalimumab | 0 | 0 | 1 (20) |
| Etanercept | 2 (50) | 2 (50) | 0 |
| Abatacept | 1 (25) | 1 (25) | 0 |
| Tocilizumab | 0 | 0 | 1 (20) |
| tsDMARD | |||
| Tofacitinib | 1 (25) | 0 | 1 (20) |
| Baricitinib | 0 | 1 (25) | 2 (40) |
| Concomitant csDMARD | |||
| Methotrexate | 2 (50) | 1 (25) | 3 (60) |
| Leflunomide | 1 (25) | 0 | 1 (20) |
| Sulfasalazine | 0 | 1 (25) | 0 |
| Concomitant hydroxychloroquine | 1 (25) | 2 (50) | 2 (40) |
| Low-dose glucocorticoids* | 2 (50) | 2 (50) | 2 (40) |
| Known contact with COVID-19 | 0 | 1 (25) | 5 (100) |
| Symptoms, n (%) | |||
| Fever | 4 (100) | 1 (25) | 0 |
| Non-productive cough | 3 (75) | 2 (50) | 0 |
| Sputum production | 1 (25) | 0 | 0 |
| Rhinorrhea | 2 (50) | 1 (25) | 0 |
| Sore throat | 0 | 0 | 0 |
| Fatigue | 4 (100) | 2 (50) | 0 |
| Myalgia | 2 (50) | 1 (25) | 0 |
| Arthralgia | 1 (25) | 1 (25) | 0 |
| Anosmia/dysgeusia | 3 (75) | 3 (75) | 0 |
| Dyspnoea at rest | 1 (25) | 0 | 0 |
| Dyspnoea on exertion | 2 (50) | 1 (25) | 0 |
| Headache | 2 (50) | 0 | 0 |
| Diarrhoea | 1 (25) | 0 | 0 |
| Nausea/vomiting | 0 | 0 | 0 |
| Chest X-ray performed | 4 (100) | 0† | 0 |
| Chest X-ray pathological findings | 0 | 0 | 0 |
| Hospital admission | 1 (25) | 0 | 0 |
*Glucocorticoids≤5 mg/day prednisone equivalent.
†Subject to home quarantine.
bDMARD, biological disease-modifying antirheumatic drug; COVID-19, coronavirus disease 2019; csDMARD, conventional synthetic disease-modifying antirheumatic drug; PA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthritis; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.